Trial Profile

Relative Bioavailability, Safety, and Tolerability Following Subcutaneous Injection of Different Doses of BI 655130 and Different Injection Sites in Healthy Male and Female Subjects (a Single Dose, Mono-centric, Open-label Study in Matched-group Design)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Spesolimab (Primary)
Indications Atopic dermatitis; Crohn's disease; Palmoplantar pustulosis; Pustular psoriasis; Ulcerative colitis
Focus Pharmacokinetics
Sponsors Boehringer Ingelheim

01 Dec 2022 Results from Phase I Clinical Studies ( NCT02525679, NCT02852824, NCT03100903, NCT03123094, NCT03617835 ) assessing pharmacokinetics of spesolimab and evaluate changes with respect to dose, frequency of dosing, formulation and injection site. Immunogenicity, safety and tolerability published in the Clinical Pharmacokinetics
06 Jun 2019 Status changed from active, no longer recruiting to completed.
04 Jun 2019 Planned End Date changed from 27 May 2019 to 5 Jun 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com